PERSONAL CFO SOLUTIONS, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.

Quarter-by-quarter ownership
PERSONAL CFO SOLUTIONS, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$472,632
+0.6%
66,7560.0%0.09%
-2.1%
Q2 2023$469,962
-16.8%
66,756
-1.5%
0.10%
-18.8%
Q1 2023$565,085
-27.0%
67,756
+0.5%
0.12%
-28.7%
Q4 2022$773,637
-8.9%
67,3900.0%0.16%
-23.0%
Q3 2022$849,000
+19.6%
67,390
+0.5%
0.21%
+27.5%
Q2 2022$710,000
-60.0%
67,088
-38.6%
0.17%
-52.3%
Q1 2022$1,775,000
+17.4%
109,1880.0%0.35%
+23.7%
Q4 2021$1,512,000
-3.6%
109,1880.0%0.28%
-12.1%
Q3 2021$1,569,000
-11.2%
109,188
-2.2%
0.32%
-11.0%
Q2 2021$1,766,000
+42.8%
111,678
-8.2%
0.36%
+35.6%
Q1 2021$1,237,000
+57.8%
121,678
+15.7%
0.27%
+37.6%
Q4 2020$784,000105,178
+15.4%
0.19%
Q3 2020$0
-100.0%
91,178
+10.3%
0.00%
-100.0%
Q2 2020$394,000
+126.4%
82,678
-5.1%
0.12%
+88.7%
Q1 2020$174,000
+58.2%
87,078
+172.1%
0.06%
+93.8%
Q4 2019$110,00032,0000.03%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2020
NameSharesValueWeighting ↓
RP Management, LLC 3,846,154$27,230,77026.28%
Prosight Management, LP 2,408,135$17,049,5965.40%
Kynam Capital Management, LP 3,133,193$22,183,0063.63%
Saturn V Capital Management LP 982,458$6,955,8032.91%
AlphaCentric Advisors LLC 649,000$4,594,9202.61%
TANG CAPITAL MANAGEMENT LLC 1,800,000$12,744,0001.80%
SILVERARC CAPITAL MANAGEMENT, LLC 791,671$5,605,0311.70%
Eversept Partners, LP 2,479,103$17,552,0491.48%
DAFNA Capital Management LLC 652,000$4,616,1601.44%
Avoro Capital Advisors LLC 11,550,000$81,774,0001.28%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders